---
title: "BUZZ-Vaccine makers fall after Trump win"
description: "Shares of vaccine manufacturers fell by 2% to 8% following Donald Trump's re-election as U.S. president. Pfizer dropped 2.4%, Moderna 5%, and Novavax 7.7%. Trump indicated he would allow Robert F. Ken"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/218966892.md"
published_at: "2024-11-06T15:13:35.000Z"
---

# BUZZ-Vaccine makers fall after Trump win

> Shares of vaccine manufacturers fell by 2% to 8% following Donald Trump's re-election as U.S. president. Pfizer dropped 2.4%, Moderna 5%, and Novavax 7.7%. Trump indicated he would allow Robert F. Kennedy Jr., an anti-vaccine advocate, to influence vaccine and healthcare policy, potentially affecting FDA and CDC operations. The implications of this shift in vaccine regulation remain uncertain, as both Trump and Kennedy have expressed intentions for significant changes in vaccine approval processes.

Shares of vaccine makers fall between 2% to 8% after Donald Trump is elected U.S. president for a second term

Pfizer (PFE.N) down 2.4%, Moderna (MRNA.O) down 5%, Novavax (NVAX.O) down 7.7%,

U.S.-listed shares of Sanofi (SASY.PA) (SNY.O) and GSK (GSK.L) (GSK.N) down 3.2% and 2.9% respectively

Trump recently said he would let former presidential candidate and anti-vaccine advocate Robert F. Kennedy Jr. “go wild,” on vaccine and healthcare policy

Kennedy said Trump promised him control over the FDA, CDC, HHS, and the USDA, which could potentially give him control over what vaccines are approved and whether Americans are recommended to receive them

Both Trump and RFK have stated their interest in dramatic change including how vaccines are regulated. But we don’t know if RFK would actually have a position of power - Leerink

PFE down 2.3%, SNY down 3.3%, GSK down 5.1% YTD

### Related Stocks

- [NVAX.US - Novavax](https://longbridge.com/en/quote/NVAX.US.md)
- [MRNA.US - Moderna](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Moderna｜10-K：2025 财年营收 19.44 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276485157.md) |
| Moderna 获得欧洲委员会对其 COVID-19 疫苗 mNEXSPIKE 的市场授权 | Moderna 已获得欧洲委员会对其 COVID-19 疫苗 mNEXSPIKE 的市场授权，适用于 12 岁及以上的个体。这标志着 Moderna 在欧盟获得的第三款疫苗，增强了其呼吸道疫苗组合。该授权在所有 27 个欧盟成员国有效，并且 | [Link](https://longbridge.com/en/news/276120116.md) |
| 期权热点｜周四 MRNA 大涨 6%，部分看涨期权飙升 241% | 美东时间 02 月 19 日，Moderna 期权总成交 124309 张，看涨期权占比 84%，看跌期权占比 15%。 | [Link](https://longbridge.com/en/news/276409384.md) |
| Moderna 第四季度收入因 COVID 疫苗销售而超出预期，流感疫苗的申请已被接受 | Moderna 第四季度的收入达到 7 亿美元，超出分析师预期，主要得益于 COVID 疫苗的销售。该公司报告的每股调整后亏损为 2.11 美元，优于预期的 2.64 美元。Moderna 的流感疫苗申请已在欧盟、加拿大和澳大利亚获得接受。 | [Link](https://longbridge.com/en/news/275897109.md) |
| 期权热点｜上周五 MRNA 大跌 5%，部分看跌期权飙升 200% | 美东时间 01 月 30 日，Moderna 期权总成交 137805 张，看涨期权占比 65%，看跌期权占比 34%。 | [Link](https://longbridge.com/en/news/274461050.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.